重组人P53腺病毒注射液局部注射联合治疗宫颈癌的疗效观察  

Recombinant human P53 adenovirus injection combined with radiotherapy in the treatment of cervical cancer

作　　者：钱叶强[1] 

机构地区：[1]安徽省枞阳县人民医院肿瘤科,246700

出　　处：《中国实用医药》2013年第5期19-20,共2页China Practical Medicine

摘　　要：目的观察重组人P53腺病毒注射液联合放疗治疗宫颈癌的疗效。方法 40例宫颈癌患者随机分为单纯放疗组(A组)和联合治疗组(B组),每组20例。重组人P53腺病毒瘤内局部注射每周1次,连用4-6次,两组放疗方案一致,治疗结束后3月,复查CT或MR观察肿瘤变化。结果联合治疗组(B组)有效率较单纯放疗组(A组)高(χ2=3.23,P<0.05)。联合治疗组发热发生率较单纯放疗组高,但发热不影响治疗过程,未增加放疗毒副反应。结论重组人P53腺病毒注射液联合放疗治疗宫颈癌具有较好疗效。Objective The effects of recombinant human P53 adenovirus injection combined with ra- diotherapy in the treatment of cervical cancer. Methods 40 cases of cervical carcinoma patients were divided randomly into therapy group （ A group） and the combined treatment group （ B group）, Each of 20 cases. Re- combinant human P53 adenovirus intratumor injection 1 times a week, 4 ~ 6 times. Two groups of radiotherapy plan agreement, After the end of treatment in March, Review of CT ＆ MR tumors observed changes. Results The combined treatment group （ group B） effective rate compared with radiotherapy alone group （ group A） high （P =0. 012）, combined treatment of febrile morbidity compared with radiotherapy alone group, But the fever does not influence the treatment process, without increasing the side reaction of radiotherapy. Conclusion Re- combinant human P53 adenovirus injection combined with radiotherapy has better curative effect in the treatment of cervical cancer.

关 键 词：P53腺病毒 宫颈癌 放疗 

分 类 号：R737.33[医药卫生—肿瘤]